Tests a personalized mRNA vaccine for hard-to-treat rhabdomyosarcoma
Tests a personalized mRNA vaccine in patients with hard-to-treat rhabdomyosarcoma.
Plain-language title generated from the registry record
Registry title: Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Early phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 6 or older with rhabdomyosarcoma that remains after standard treatment and has no effective treatment option left. It tests a personalized mRNA vaccine.
- Age
- 6 years or older
- Sex
- All sexes can join.
- Disease stage
- Rhabdomyosarcoma confirmed by pathology or molecular testing, with leftover tumor or slight progression after standard treatment and no effective treatment option available.
- Earlier treatment
- Must have had standard therapy. Continuing the earlier anti-cancer treatment is allowed while the vaccine is being made.
Main reasons for not taking part
- Another untreated cancer (some earlier treated skin, cervical or superficial bladder cancers are allowed)
- Past or current active autoimmune disease
- Uncontrolled heart or blood vessel disease
- Expected survival of 6 months or less
- ECOG performance status above 1
Read by machine on 9 November 2026.
Where in China
- Chinese PLA General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinxin Zhang
- Trial code
- NCT06932861
- Record updated
- 26 October 2026
- Original description
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory RhabdomyosarcomaRead full original descriptionShow less
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Inclusion: Diagnosed with rhabdomyosarcoma confirmed by pathological or molecular testing; Age ≥ 6 years; Has residual tumor or minor disease progression following standard therapy, and has no available effective treatment option. (*: Prior to vaccine administration, during the vaccine manufacturing period, continuation of the prior antitumor regimen is permitted in combination with the study drug(s).); Expected survival time greater than 6 months; ECOG performance status score of 0-1; -.
Exclusion: 1.History of or concurrent with other untreated malignant tumors, except for previously cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and superficial bladder cancer; 2.History of or current active autoimmune diseases. 3.Has uncontrolled cardiovascular diseases.